TY - JOUR
T1 - Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations
AU - Talip, Zeynep
AU - Borgna, Francesca
AU - Müller, Cristina
AU - Ulrich, Jiri
AU - Duchemin, Charlotte
AU - Fernandes Pinto Ramos, João Pedro
AU - Stora, Thierry
AU - Köster, Ulli
AU - Nedjadi, Youcef
AU - Maratovich Gadelshin, Vadim
AU - Fedosseev, Valentin N.
AU - Juget, Frederic
AU - Bailat, Claude J.
AU - Fankhauser, Adelheid
AU - Wilkins, Shane
AU - Lambert, Laura
AU - Marsh, Bruce A
AU - Fedorov, Dmitry
AU - Chevallay, Eric
AU - Fernier, Pascal
AU - Schibli, Roger
AU - van der Meulen, Nicholas P.
N1 - Score=10
PY - 2021/4/22
Y1 - 2021/4/22
N2 - The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.
AB - The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.
KW - Er-169
KW - Electromagnetic isotope separation
KW - Lanthanide-separation
KW - Activity standardization
KW - In vitro studies
KW - Laser resonance ionization
UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/45021037
U2 - 10.3389/fmed.2021.643175
DO - 10.3389/fmed.2021.643175
M3 - Article
SN - 2296-858X
VL - 8
SP - 1
EP - 11
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 643175
ER -